DARVON-N
LOE Approachingpropoxyphene napsylate
NDAORALTABLET
Approved
Sep 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DARVON-N (propoxyphene napsylate) is clinical pharmacology pharmacology propoxyphene is a centrally acting opiate analgesic. First approved in 1971.
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DARVON-N (propoxyphene napsylate) is an oral, centrally acting opioid analgesic approved in 1971 for pain management. It works through mu-opioid receptor agonism and also exhibits local anesthetic and cardiac ion-channel blocking properties via sodium and potassium channel inhibition. The drug is administered as tablets and is indicated for mild-to-moderate pain relief.
LOE Approaching
Product is approaching loss of exclusivity with minimal market activity, indicating a declining commercial team and limited career growth opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacology Propoxyphene is a centrally acting opiate analgesic. In vitro studies demonstrated propoxyphene and the metabolite norpropoxyphene inhibit sodium channels (local anesthetic effect) with norpropoxyphene being approximately 2-fold more potent than propoxyphene and…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.